# Voyager Therapeutics (VYGR) — Earnings

VYGR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vygr/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.47 |
| EPS estimate | −$0.52 |
| EPS surprise | +9.77% |
| Revenue surprise | +70.00% |
| Revenue | $13.4M |
| Revenue estimate | $7.9M |
| Reported | Nov 10, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1640266/000110465925108846/vygr-20250930x10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/format/e57e89a4-e83d-92f3-01eb-4df48b332f67.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 10, 2025 | −$0.52 | −$0.47 | 9.77% | $7.9M | $13.4M |
| Q2 2025 | Aug 6, 2025 | −$0.53 | −$0.57 | -8.45% | $9.9M | $5.2M |
| Q1 2025 | May 6, 2025 | −$0.45 | −$0.53 | -18.12% | $13.9M | $6.5M |
| Q4 2024 | Mar 11, 2025 | −$0.37 | −$0.59 | -60.89% | $16.6M | $6.3M |
| Q3 2024 | Nov 12, 2024 | −$0.44 | −$0.16 | 64.03% | $11.7M | $24.6M |
| Q2 2024 | Aug 6, 2024 | −$0.41 | −$0.18 | 56.00% | $9.5M | $29.6M |
| Q1 2024 | May 13, 2024 | −$0.44 | −$0.20 | 54.47% | $9.5M | $19.5M |
| Q4 2023 | Feb 28, 2024 | −$0.29 | $1.25 | 532.53% | $20.6M | $90.1M |
| Q3 2023 | Nov 6, 2023 | −$0.58 | −$0.59 | -1.53% | $2.9M | $4.6M |
| Q2 2023 | Aug 3, 2023 | −$0.57 | −$0.51 | 10.34% | $1.6M | $4.9M |
| Q1 2023 | May 9, 2023 | −$0.33 | $2.94 | 1004.62% | $10.0M | $150.5M |
| Q4 2022 | Mar 7, 2023 | −$0.55 | −$0.61 | -11.78% | $3.7M | — |
| Q3 2022 | Nov 8, 2022 | −$0.32 | $0.45 | 241.91% | $9.4M | $41.1M |
| Q2 2022 | Aug 4, 2022 | −$0.48 | −$0.50 | -4.80% | $7.0M | $712,000.00 |
| Q1 2022 | May 4, 2022 | −$0.37 | −$0.56 | -50.98% | $12.7M | $658,000.00 |
| Q4 2021 | Mar 8, 2022 | −$0.62 | $0.15 | 124.05% | $4.3M | $28.1M |
| Q3 2021 | Nov 2, 2021 | −$0.75 | −$0.67 | 10.37% | $2.1M | $1.5M |
| Q2 2021 | Aug 9, 2021 | −$0.73 | −$0.80 | -9.91% | $4.2M | $1.4M |
| Q1 2021 | May 10, 2021 | −$0.64 | −$0.58 | 9.90% | $7.5M | $6.5M |
| Q4 2020 | Feb 25, 2021 | −$0.56 | −$0.43 | 23.21% | $16.6M | $6.5M |

## Frequently Asked Questions

### When did Voyager Therapeutics (VYGR) last report earnings?

Voyager Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.

### Did VYGR beat earnings estimates?

Yes. Voyager Therapeutics reported EPS of −$0.47 for Q3 2025 against a −$0.52 estimate — a 9.77% beat.

### How much revenue did VYGR report last quarter?

Voyager Therapeutics reported $13.4M in revenue for Q3 2025, against a consensus estimate of $7.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).